5 year outcomes in patients with RAP treated with Aflibercept
Research type
Research Study
Full title
A non-interventional study investigating the 5 year visual and anatomical outcomes in patients with the retinal angiomatous proliferation (RAP) subtype of wet age-related macular degeneration, treated with intravitreal Aflibercept (Eylea) as part of their routine care
IRAS ID
276158
Contact name
Andrew Browning
Contact email
Sponsor organisation
Newcastle Upon Tyne Hospitals Foundation Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Retinal angiomatous proliferation (RAP) is a distinct form of wet age-related macular degeneration (AMD). Studies demonstrate that the entity is present in approximately 8-15% of all cases of wet AMD and that most patients develop a similar lesion in their fellow eye within 3 years of the first eye being diagnosed. Until recently, it was thought that the diagnosis of RAP in a patient with untreated neovascular AMD was linked to a poor visual prognosis, especially when
compared with untreated non-RAP wet AMD cases. Until the advent of anti-VEGF treatments, it was widely accepted that there was a general lack of response of RAP lesions to previously available interventions such as focal argon laser, photodynamic therapy or transpupillary thermotherapy. We showed in a previous study that after 2 years of treatment with intravitreal Aflibercept, RAP patient did as well as those with the more common form of wet AMD
The aim of this study is to collect data retrospectively on the visual and anatomical outcomes of patients undergoing aflibercept treatment for wet AMD who have previously been identified in a 2 year prospective study (IRAS 172260) as having the RAP subtype of disease over the following 3 years of follow up(5 years total)
By investigating patients vision and optical coherence tomography (OCT) scans we aim to improve our understanding of the effectiveness of treatment over the long term . The study does not involve any change to the patients normal management.REC name
London - Westminster Research Ethics Committee
REC reference
20/PR/0562
Date of REC Opinion
14 Oct 2020
REC opinion
Favourable Opinion